Oxford Metrics (OMG) investor relations material

Trading outlook

• Trading since the March 2026 interim period was below Board expectations, reflecting changes in Vicon markets, constrained research funding and IVMS project delays.

• FY26 is a 15-month period to 31 December 2026; revenue is expected at £47.0m–£51.0m and adjusted EBIT at a loss of £0.5m–£3.9m, below market expectations of £56.2m revenue and £3.0m profit.

• FY27 adjusted EBIT is expected at or above the £3.5m market expectation, while revenue is expected below the £52.5m market expectation.

• The FY26 range reflects uncertainty over the timing and conversion of larger near-term customer opportunities.

Vicon strategy and trading

• Entertainment demand was affected by lower film, TV and games investment; constrained research funding continued to delay health and life sciences purchases, while robotics demand remained encouraging.

• Orders from major robotics companies and opportunities in humanoid robotics and drone tracking support expansion from research programmes into wider deployment.

• The move:ai acquisition is intended to accelerate markerless technology and broaden customer access; hybrid systems and exclusive rights to a substantial movement dataset add to Vicon's technology and data base.

• Nexus Markerless launched for health and life sciences via recurring subscriptions; a new Vero camera supports upgrades and new installations, while Captive Devices adds facial capture.

IVMS progress

• The FY26 revenue range assumes no contribution from the delayed next phase of a major contact lens inspection programme, now expected in Q1 2027.

• IVMS removed lower-margin distribution products, reducing near-term revenue while refocusing sales on applications with greater technical value and stronger margins.

• Three repeatable inspection offerings were developed across optical inspection, medical equipment and semiconductor applications; pilot systems have sold in the latter two areas.